Answers are grounded in this paper and cite their sources.
Experimental study demonstrates SAK3 promotes neuronal survival and mitochondrial function in Parkinson's models, indicating the SphK1/S1P axis as a therapeutic target.
Parkinson’s disease (PD) involves dopaminergic neuron loss linked to calcium imbalance. Although calcium channel blockers have shown limited efficacy, SAK3 is a known selective enhancer of the T-type calcium channel Cav3.1. While it shows neuroprotective potential, its precise downstream mechanisms in Parkinson’s disease (PD) remain unclear. We found Cav3.1, the principal T-type channel in the substantia nigra, is downregulated in PD models and patient tissues. In a pretreatment paradigm, SAK3 restored Cav3.1 function, improving motor deficits, neuronal survival, and mitochondrial integrity. Metabolomic analysis revealed SAK3 drives metabolic shifts toward glycine/serine pathways and enriches mitochondrial oxidative phosphorylation genes. Mechanistically, SAK3 promotes calcium influx, activating the SphK1/S1P/Akt pathway to enhance mitochondrial function—stabilizing membrane potential, boosting oxidative phosphorylation, and rebalancing apoptosis regulators. Collectively, our study suggests that the effects of SAK3 are associated with Cav3.1 activationl and it orchestrates a protective response in preventive PD models by engaging the SphK1/S1P signaling axis, thereby stabilizing mitochondria and inhibiting apoptosis. These findings reveal a potential downstream effector pathway associated with Cav3.1 activation and position the SphK1/S1P network as a promising therapeutic target for further investigation in PD.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: